Active Filter(s):
Details:
Versiti has been granted three multi-center research contracts to coordinate nationwide clinical trials aimed at establishing optimal treatment plans for preventing blood clots in people with COVID-19. The contracts were awarded to Versiti by the University of Pittsburgh with funding by National Institutes of Health (NIH).
Lead Product(s): Heparin Sodium
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 29, 2021